Related Experiment Video
Updated: May 16, 2026
07:17
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
Sied Kebir1, Klaus Kuchelmeister, Pitt Niehusmann
1Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany. Ulrich.Herrlinger@ukb.uni-bonn.de.
Experimental Hematology & Oncology
|December 11, 2012
Summary
High-dose methotrexate and rituximab show success in treating a rare CNS lymphoma. This therapy led to complete remission in a patient with intravascular diffuse large B-cell lymphoma of the CNS.
Area of Science:
- Neurology
- Hematology
- Oncology
Background:
- Intravascular diffuse large B-cell lymphoma of the CNS (cIVL) is a rare malignancy.
- cIVL selectively affects CNS blood vessels, sparing brain parenchyma.
- Previous treatments with anthracyclines yielded poor outcomes.
Observation:
- A case of cIVL is presented.
- The patient received high-dose methotrexate-based polychemotherapy (Bonn protocol) combined with rituximab.
Findings:
- The combined therapy resulted in complete clinical and MRI remission.
- Remission has been sustained for 29 months post-diagnosis.
Implications:
- This treatment regimen offers a promising therapeutic strategy for cIVL.
- Successful management of cIVL may improve patient survival and quality of life.
